National Services Division

Dundee Somatic Cancer Testing

22 October 2021



© SCMG 2021

Discussion

- Analysis based on Dundee data provided for Somatic Testing for Solid Tumours and Haematological Malignancies 2019 -2020,
  - Germline testing has been analysed and provided separately,
- Data Analysis to consider how current workload could be illustrated and support future capacity planning for the SGLC service and potential what-if scenarios based on future and changing demand requirements.

© SCMG 2021

Dundee Lab Somatic Testing 2019 – 2020 Samples In



© SCMG 2021

Dundee Lab Somatic Testing 2019 – 2020 Samples In



© SCMG 2021

Dundee Samples Received Solid Tumour 2019 - 2020



© SCMG 2021

Dundee Samples Received – Haematological Malignancies 2019 - 2020



© SCMG 2021

Dundee Number of Tests by Method



© SCMG 2021

Dundee Number of Tests by Method – Solid Tumours and Haematological Malignancies



© SCMG 2021

Dundee Somatic Testing – Activity for Solid Tumours and Haematological Malignancies



© SCMG 2021

Dundee 2019-2020 Somatic Samples In and Tests by Cancer Type



© SCMG 2021

Dundee Average Number of Tests by Sample for each Cancer Type



© SCMG 2021

Discussion

- Complexity and duration of tests is not considered at this point in the analysis,
- Analysis does not consider resources or equipment required to meet demand,
- There are clear and distinct patterns in the data related to the “volume” of activity,
- Not to confuse high volume of samples with relatively few tests and low volumes of samples with higher numbers of test and complexity,
- Workload should be considered as a function of the number of samples, tests and reports which can all be quantified,
- TATs not analysed at this point,
- Explore explicit link to Outcomes for Patients for different Categories and Types.

© SCMG 2021